Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
N-803 and Rituximab in Relapsed/Refractory Indolent B-cell NHL
NCT02384954Phase 2Terminated
- Sponsor
- Altor BioScience Corporation
- Start
- Apr 2015
- Primary completion
- Dec 2020
- Modality
- Cytokines & Interferons, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, open-label trial of nogapendekin alfa inbakicept in B-cell non-Hodgkin lymphoma (9 cohorts), sponsored by Altor BioScience Corporation. Primary endpoints: Maximum Tolerated Dose or Minimum Efficacious Dose at 9 months, Treatment Emergent Adverse Events at 40 weeks and 1 more. Started Apr 2015; status: terminated.
02
Drugs
nogapendekin alfa inbakicept
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT02384954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02384954.